Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 14 entries
Sorted by: Best Match Show Resources per page
Indoleamine-2,3-dioxygenase activity in experimental human endotoxemia.

Experimental & translational stroke medicine

Padberg JS, Van Meurs M, Kielstein JT, Martens-Lobenhoffer J, Bode-Böger SM, Zijlstra JG, Kovesdy CP, Kümpers P.
PMID: 23216784
Exp Transl Stroke Med. 2012 Dec 05;4(1):24. doi: 10.1186/2040-7378-4-24.

BACKGROUND: Excessive tryptophan metabolism to kynurenine by the rate-limiting enzyme endothelial indoleamine 2,3-dioxygenase 1 (IDO) controls arterial vessel relaxation and causes hypotension in murine endotoxemia. However, its relevance in human endotoxemia has not been investigated so far. We thus...

Cite
Padberg JS, Van Meurs M, Kielstein JT, et al. Indoleamine-2,3-dioxygenase activity in experimental human endotoxemia. Exp Transl Stroke Med. 2012;4(1):24doi: 10.1186/2040-7378-4-24.
Padberg, J. S., Van Meurs, M., Kielstein, J. T., Martens-Lobenhoffer, J., Bode-Böger, S. M., Zijlstra, J. G., Kovesdy, C. P., & Kümpers, P. (2012). Indoleamine-2,3-dioxygenase activity in experimental human endotoxemia. Experimental & translational stroke medicine, 4(1), 24. https://doi.org/10.1186/2040-7378-4-24
Padberg, Jan-Sören, et al. "Indoleamine-2,3-dioxygenase activity in experimental human endotoxemia." Experimental & translational stroke medicine vol. 4,1 (2012): 24. doi: https://doi.org/10.1186/2040-7378-4-24
Padberg JS, Van Meurs M, Kielstein JT, Martens-Lobenhoffer J, Bode-Böger SM, Zijlstra JG, Kovesdy CP, Kümpers P. Indoleamine-2,3-dioxygenase activity in experimental human endotoxemia. Exp Transl Stroke Med. 2012 Dec 05;4(1):24. doi: 10.1186/2040-7378-4-24. PMID: 23216784; PMCID: PMC3560239.
Copy Download .nbib Format: NLM
Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Martens-Lobenhoffer J, Tomaras S, Feist E, Bode-Böger SM.
PMID: 34871917
J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Jan 01;1188:123076. doi: 10.1016/j.jchromb.2021.123076. Epub 2021 Dec 01.

Upadacitinib is a selective janus-kinase-1 inhibitor effective in the treatment of autoimmune related diseases like rheumatoid arthritis or psoriatic arthritis. Here, we described a LC-MS/MS method for the quantification of upadacitinib in human plasma applicable for therapeutic drug monitoring....

Cite
Martens-Lobenhoffer J, Tomaras S, Feist E, et al. Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1188:123076doi: 10.1016/j.jchromb.2021.123076.
Martens-Lobenhoffer, J., Tomaras, S., Feist, E., & Bode-Böger, S. M. (2022). Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1188123076. https://doi.org/10.1016/j.jchromb.2021.123076
Martens-Lobenhoffer, Jens, et al. "Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS." Journal of chromatography. B, Analytical technologies in the biomedical and life sciences vol. 1188 (2022): 123076. doi: https://doi.org/10.1016/j.jchromb.2021.123076
Martens-Lobenhoffer J, Tomaras S, Feist E, Bode-Böger SM. Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Jan 01;1188:123076. doi: 10.1016/j.jchromb.2021.123076. Epub 2021 Dec 01. PMID: 34871917.
Copy Download .nbib Format: NLM
Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Martens-Lobenhoffer J, Tomaras S, Feist E, Bode-Böger SM.
PMID: 34871917
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Dec 01;1188:123076. doi: 10.1016/j.jchromb.2021.123076. Epub 2021 Dec 01.

Upadacitinib is a selective janus-kinase-1 inhibitor effective in the treatment of autoimmune related diseases like rheumatoid arthritis or psoriatic arthritis. Here, we described a LC-MS/MS method for the quantification of upadacitinib in human plasma applicable for therapeutic drug monitoring....

Cite
Martens-Lobenhoffer J, Tomaras S, Feist E, et al. Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1188:123076doi: 10.1016/j.jchromb.2021.123076.
Martens-Lobenhoffer, J., Tomaras, S., Feist, E., & Bode-Böger, S. M. (2021). Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1188123076. https://doi.org/10.1016/j.jchromb.2021.123076
Martens-Lobenhoffer, Jens, et al. "Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS." Journal of chromatography. B, Analytical technologies in the biomedical and life sciences vol. 1188 (2021): 123076. doi: https://doi.org/10.1016/j.jchromb.2021.123076
Martens-Lobenhoffer J, Tomaras S, Feist E, Bode-Böger SM. Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Dec 01;1188:123076. doi: 10.1016/j.jchromb.2021.123076. Epub 2021 Dec 01. PMID: 34871917.
Copy Download .nbib Format: NLM
Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Martens-Lobenhoffer J, Tomaras S, Feist E, Bode-Böger SM.
PMID: 34871917
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Dec 01;1188:123076. doi: 10.1016/j.jchromb.2021.123076. Epub 2021 Dec 01.

Upadacitinib is a selective janus-kinase-1 inhibitor effective in the treatment of autoimmune related diseases like rheumatoid arthritis or psoriatic arthritis. Here, we described a LC-MS/MS method for the quantification of upadacitinib in human plasma applicable for therapeutic drug monitoring....

Cite
Martens-Lobenhoffer J, Tomaras S, Feist E, et al. Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1188:123076doi: 10.1016/j.jchromb.2021.123076.
Martens-Lobenhoffer, J., Tomaras, S., Feist, E., & Bode-Böger, S. M. (2021). Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1188123076. https://doi.org/10.1016/j.jchromb.2021.123076
Martens-Lobenhoffer, Jens, et al. "Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS." Journal of chromatography. B, Analytical technologies in the biomedical and life sciences vol. 1188 (2021): 123076. doi: https://doi.org/10.1016/j.jchromb.2021.123076
Martens-Lobenhoffer J, Tomaras S, Feist E, Bode-Böger SM. Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Dec 01;1188:123076. doi: 10.1016/j.jchromb.2021.123076. Epub 2021 Dec 01. PMID: 34871917.
Copy Download .nbib Format: NLM
Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Martens-Lobenhoffer J, Tomaras S, Feist E, Bode-Böger SM.
PMID: 34871917
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Dec 01;1188:123076. doi: 10.1016/j.jchromb.2021.123076. Epub 2021 Dec 01.

Upadacitinib is a selective janus-kinase-1 inhibitor effective in the treatment of autoimmune related diseases like rheumatoid arthritis or psoriatic arthritis. Here, we described a LC-MS/MS method for the quantification of upadacitinib in human plasma applicable for therapeutic drug monitoring....

Cite
Martens-Lobenhoffer J, Tomaras S, Feist E, et al. Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1188:123076doi: 10.1016/j.jchromb.2021.123076.
Martens-Lobenhoffer, J., Tomaras, S., Feist, E., & Bode-Böger, S. M. (2021). Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1188123076. https://doi.org/10.1016/j.jchromb.2021.123076
Martens-Lobenhoffer, Jens, et al. "Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS." Journal of chromatography. B, Analytical technologies in the biomedical and life sciences vol. 1188 (2021): 123076. doi: https://doi.org/10.1016/j.jchromb.2021.123076
Martens-Lobenhoffer J, Tomaras S, Feist E, Bode-Böger SM. Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Dec 01;1188:123076. doi: 10.1016/j.jchromb.2021.123076. Epub 2021 Dec 01. PMID: 34871917.
Copy Download .nbib Format: NLM
Higher levels of SDMA and not ADMA are associated with poorer survival of trial patients with systemic ANCA-associated vasculitis.

European journal of rheumatology

Erdbrügger U, Kielstein JT, Westman K, Ma JZ, Xin W, Bode-Böger SM, Segelmark M, Rasmussen N, De Groot K.
PMID: 30071927
Eur J Rheumatol. 2018 Sep;5(3):153-159. doi: 10.5152/eurjrheum.2018.17119. Epub 2018 Apr 02.

OBJECTIVE: Endothelial dysfunction, increased cardiovascular events (CVE), and accelerated atherosclerosis have been described in patients with small vessel vasculitis and collagen vascular disease. Identifying predictors of cardiovascular risk will help to optimize short- and long-term care of patients with...

Cite
Erdbrügger U, Kielstein JT, Westman K, et al. Higher levels of SDMA and not ADMA are associated with poorer survival of trial patients with systemic ANCA-associated vasculitis. Eur J Rheumatol. 2018;5(3):153-159doi: 10.5152/eurjrheum.2018.17119.
Erdbrügger, U., Kielstein, J. T., Westman, K., Ma, J. Z., Xin, W., Bode-Böger, S. M., Segelmark, M., Rasmussen, N., & De Groot, K. (2018). Higher levels of SDMA and not ADMA are associated with poorer survival of trial patients with systemic ANCA-associated vasculitis. European journal of rheumatology, 5(3), 153-159. https://doi.org/10.5152/eurjrheum.2018.17119
Erdbrügger, Uta, et al. "Higher levels of SDMA and not ADMA are associated with poorer survival of trial patients with systemic ANCA-associated vasculitis." European journal of rheumatology vol. 5,3 (2018): 153-159. doi: https://doi.org/10.5152/eurjrheum.2018.17119
Erdbrügger U, Kielstein JT, Westman K, Ma JZ, Xin W, Bode-Böger SM, Segelmark M, Rasmussen N, De Groot K. Higher levels of SDMA and not ADMA are associated with poorer survival of trial patients with systemic ANCA-associated vasculitis. Eur J Rheumatol. 2018 Sep;5(3):153-159. doi: 10.5152/eurjrheum.2018.17119. Epub 2018 Apr 02. PMID: 30071927; PMCID: PMC6116852.
Copy Download .nbib Format: NLM
Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Martens-Lobenhoffer J, Tomaras S, Feist E, Bode-Böger SM.
PMID: 34871917
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Dec 01;1188:123076. doi: 10.1016/j.jchromb.2021.123076. Epub 2021 Dec 01.

Upadacitinib is a selective janus-kinase-1 inhibitor effective in the treatment of autoimmune related diseases like rheumatoid arthritis or psoriatic arthritis. Here, we described a LC-MS/MS method for the quantification of upadacitinib in human plasma applicable for therapeutic drug monitoring....

Cite
Martens-Lobenhoffer J, Tomaras S, Feist E, et al. Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1188:123076doi: 10.1016/j.jchromb.2021.123076.
Martens-Lobenhoffer, J., Tomaras, S., Feist, E., & Bode-Böger, S. M. (2021). Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1188123076. https://doi.org/10.1016/j.jchromb.2021.123076
Martens-Lobenhoffer, Jens, et al. "Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS." Journal of chromatography. B, Analytical technologies in the biomedical and life sciences vol. 1188 (2021): 123076. doi: https://doi.org/10.1016/j.jchromb.2021.123076
Martens-Lobenhoffer J, Tomaras S, Feist E, Bode-Böger SM. Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Dec 01;1188:123076. doi: 10.1016/j.jchromb.2021.123076. Epub 2021 Dec 01. PMID: 34871917.
Copy Download .nbib Format: NLM
Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Martens-Lobenhoffer J, Tomaras S, Feist E, Bode-Böger SM.
PMID: 34871917
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Dec 01;1188:123076. doi: 10.1016/j.jchromb.2021.123076. Epub 2021 Dec 01.

Upadacitinib is a selective janus-kinase-1 inhibitor effective in the treatment of autoimmune related diseases like rheumatoid arthritis or psoriatic arthritis. Here, we described a LC-MS/MS method for the quantification of upadacitinib in human plasma applicable for therapeutic drug monitoring....

Cite
Martens-Lobenhoffer J, Tomaras S, Feist E, et al. Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1188:123076doi: 10.1016/j.jchromb.2021.123076.
Martens-Lobenhoffer, J., Tomaras, S., Feist, E., & Bode-Böger, S. M. (2021). Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1188123076. https://doi.org/10.1016/j.jchromb.2021.123076
Martens-Lobenhoffer, Jens, et al. "Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS." Journal of chromatography. B, Analytical technologies in the biomedical and life sciences vol. 1188 (2021): 123076. doi: https://doi.org/10.1016/j.jchromb.2021.123076
Martens-Lobenhoffer J, Tomaras S, Feist E, Bode-Böger SM. Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Dec 01;1188:123076. doi: 10.1016/j.jchromb.2021.123076. Epub 2021 Dec 01. PMID: 34871917.
Copy Download .nbib Format: NLM
Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Martens-Lobenhoffer J, Tomaras S, Feist E, Bode-Böger SM.
PMID: 34871917
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Dec 01;1188:123076. doi: 10.1016/j.jchromb.2021.123076. Epub 2021 Dec 01.

Upadacitinib is a selective janus-kinase-1 inhibitor effective in the treatment of autoimmune related diseases like rheumatoid arthritis or psoriatic arthritis. Here, we described a LC-MS/MS method for the quantification of upadacitinib in human plasma applicable for therapeutic drug monitoring....

Cite
Martens-Lobenhoffer J, Tomaras S, Feist E, et al. Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1188:123076doi: 10.1016/j.jchromb.2021.123076.
Martens-Lobenhoffer, J., Tomaras, S., Feist, E., & Bode-Böger, S. M. (2021). Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1188123076. https://doi.org/10.1016/j.jchromb.2021.123076
Martens-Lobenhoffer, Jens, et al. "Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS." Journal of chromatography. B, Analytical technologies in the biomedical and life sciences vol. 1188 (2021): 123076. doi: https://doi.org/10.1016/j.jchromb.2021.123076
Martens-Lobenhoffer J, Tomaras S, Feist E, Bode-Böger SM. Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Dec 01;1188:123076. doi: 10.1016/j.jchromb.2021.123076. Epub 2021 Dec 01. PMID: 34871917.
Copy Download .nbib Format: NLM
Mixed experiences with commercial calibrators and controls for COVID-19 drugs.

The journal of applied laboratory medicine

Martens-Lobenhoffer J, Bode-Böger SM.
PMID: 34633412
J Appl Lab Med. 2021 Oct 11; doi: 10.1093/jalm/jfab130. Epub 2021 Oct 11.

No abstract available.

Cite
Martens-Lobenhoffer J, Bode-Böger SM. Mixed experiences with commercial calibrators and controls for COVID-19 drugs. J Appl Lab Med. 2021;doi: 10.1093/jalm/jfab130.
Martens-Lobenhoffer, J., & Bode-Böger, S. M. (2021). Mixed experiences with commercial calibrators and controls for COVID-19 drugs. The journal of applied laboratory medicine, . https://doi.org/10.1093/jalm/jfab130
Martens-Lobenhoffer, Jens, and Bode-Böger, Stefanie M. "Mixed experiences with commercial calibrators and controls for COVID-19 drugs." The journal of applied laboratory medicine vol. (2021). doi: https://doi.org/10.1093/jalm/jfab130
Martens-Lobenhoffer J, Bode-Böger SM. Mixed experiences with commercial calibrators and controls for COVID-19 drugs. J Appl Lab Med. 2021 Oct 11; doi: 10.1093/jalm/jfab130. Epub 2021 Oct 11. PMID: 34633412; PMCID: PMC8524534.
Copy Download .nbib Format: NLM
Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Martens-Lobenhoffer J, Tomaras S, Feist E, Bode-Böger SM.
PMID: 34871917
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Dec 01;1188:123076. doi: 10.1016/j.jchromb.2021.123076. Epub 2021 Dec 01.

Upadacitinib is a selective janus-kinase-1 inhibitor effective in the treatment of autoimmune related diseases like rheumatoid arthritis or psoriatic arthritis. Here, we described a LC-MS/MS method for the quantification of upadacitinib in human plasma applicable for therapeutic drug monitoring....

Cite
Martens-Lobenhoffer J, Tomaras S, Feist E, et al. Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1188:123076doi: 10.1016/j.jchromb.2021.123076.
Martens-Lobenhoffer, J., Tomaras, S., Feist, E., & Bode-Böger, S. M. (2021). Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1188123076. https://doi.org/10.1016/j.jchromb.2021.123076
Martens-Lobenhoffer, Jens, et al. "Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS." Journal of chromatography. B, Analytical technologies in the biomedical and life sciences vol. 1188 (2021): 123076. doi: https://doi.org/10.1016/j.jchromb.2021.123076
Martens-Lobenhoffer J, Tomaras S, Feist E, Bode-Böger SM. Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Dec 01;1188:123076. doi: 10.1016/j.jchromb.2021.123076. Epub 2021 Dec 01. PMID: 34871917.
Copy Download .nbib Format: NLM
Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Martens-Lobenhoffer J, Tomaras S, Feist E, Bode-Böger SM.
PMID: 34871917
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Dec 01;1188:123076. doi: 10.1016/j.jchromb.2021.123076. Epub 2021 Dec 01.

Upadacitinib is a selective janus-kinase-1 inhibitor effective in the treatment of autoimmune related diseases like rheumatoid arthritis or psoriatic arthritis. Here, we described a LC-MS/MS method for the quantification of upadacitinib in human plasma applicable for therapeutic drug monitoring....

Cite
Martens-Lobenhoffer J, Tomaras S, Feist E, et al. Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1188:123076doi: 10.1016/j.jchromb.2021.123076.
Martens-Lobenhoffer, J., Tomaras, S., Feist, E., & Bode-Böger, S. M. (2021). Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1188123076. https://doi.org/10.1016/j.jchromb.2021.123076
Martens-Lobenhoffer, Jens, et al. "Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS." Journal of chromatography. B, Analytical technologies in the biomedical and life sciences vol. 1188 (2021): 123076. doi: https://doi.org/10.1016/j.jchromb.2021.123076
Martens-Lobenhoffer J, Tomaras S, Feist E, Bode-Böger SM. Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Dec 01;1188:123076. doi: 10.1016/j.jchromb.2021.123076. Epub 2021 Dec 01. PMID: 34871917.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 14 entries